AU7930987A

AU7930987A – Human macrophage migration inhibition factor related peptide
– Google Patents

AU7930987A – Human macrophage migration inhibition factor related peptide
– Google Patents
Human macrophage migration inhibition factor related peptide

Info

Publication number
AU7930987A

AU7930987A
AU79309/87A
AU7930987A
AU7930987A
AU 7930987 A
AU7930987 A
AU 7930987A
AU 79309/87 A
AU79309/87 A
AU 79309/87A
AU 7930987 A
AU7930987 A
AU 7930987A
AU 7930987 A
AU7930987 A
AU 7930987A
Authority
AU
Australia
Prior art keywords
related peptide
factor related
macrophage migration
human macrophage
inhibition factor
Prior art date
1986-10-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Application number
AU79309/87A
Inventor
Josef Bruggen
Nico Cerletti
Roger Clerc
Karel Gerrit Odink
Clemens Sorg
Lajos Tarcsay
Walter Wiesendanger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1986-10-03
Filing date
1987-10-02
Publication date
1988-05-19

1986-10-03
Priority claimed from GB868623850A
external-priority
patent/GB8623850D0/en

1986-11-27
Priority claimed from GB868628358A
external-priority
patent/GB8628358D0/en

1987-10-02
Application filed by Ciba Geigy AG
filed
Critical
Ciba Geigy AG

1988-05-19
Publication of AU7930987A
publication
Critical
patent/AU7930987A/en

Status
Abandoned
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

102000009073
Macrophage Migration-Inhibitory Factors
Human genes

0.000
title
1

108010048043
Macrophage Migration-Inhibitory Factors
Proteins

0.000
title
1

108090000765
processed proteins & peptides
Proteins

0.000
title
1

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

C07K14/52—Cytokines; Lymphokines; Interferons

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

C12N15/09—Recombinant DNA-technology

C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts

C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K38/00—Medicinal preparations containing peptides

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N2830/00—Vector systems having a special element relevant for transcription

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N2830/00—Vector systems having a special element relevant for transcription

C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination

C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N2830/00—Vector systems having a special element relevant for transcription

C12N2830/55—Vector systems having a special element relevant for transcription from bacteria

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N2830/00—Vector systems having a special element relevant for transcription

C12N2830/70—Vector systems having a special element relevant for transcription from fungi

C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast

AU79309/87A
1986-10-03
1987-10-02
Human macrophage migration inhibition factor related peptide

Abandoned

AU7930987A
(en)

Applications Claiming Priority (4)

Application Number
Priority Date
Filing Date
Title

GB868623850A

GB8623850D0
(en)

1986-10-03
1986-10-03
Lymphokine related peptide

GB8628358

1986-11-27

GB8623850

1986-11-27

GB868628358A

GB8628358D0
(en)

1986-11-27
1986-11-27
Lymphokine related peptides

Publications (1)

Publication Number
Publication Date

AU7930987A
true

AU7930987A
(en)

1988-05-19

Family
ID=26291377
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU79309/87A
Abandoned

AU7930987A
(en)

1986-10-03
1987-10-02
Human macrophage migration inhibition factor related peptide

Country Status (11)

Country
Link

US
(2)

US5350687A
(en)

EP
(1)

EP0263072B1
(en)

JP
(1)

JPH09188698A
(en)

AU
(1)

AU7930987A
(en)

DE
(1)

DE3789413T2
(en)

DK
(1)

DK517787A
(en)

ES
(1)

ES2052602T3
(en)

FI
(1)

FI874287A
(en)

IE
(1)

IE61773B1
(en)

NO
(1)

NO874159L
(en)

PT
(1)

PT85849B
(en)

Cited By (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU649226B2
(en)

*

1989-07-05
1994-05-19
Novartis Ag
Novel cytokines

Families Citing this family (29)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

FR2750604B1
(en)

*

1996-07-02
2002-09-20
Oreal

HETEROMER BINDING ARACHIDONIC ACID AND ITS USE IN COSMETICS OR PHARMACY

CA2050332A1
(en)

*

1989-03-17
1990-09-18
Steven C. Clark
Human macrophage migration inhibitory factor

JP2747839B2
(en)

*

1989-08-14
1998-05-06
花王株式会社

Monoclonal antibody

US5149544A
(en)

*

1989-11-13
1992-09-22
Research Corporation Technologies, Inc.
Method of inhibiting progenitor cell proliferation

DE69133159D1
(en)

*

1990-09-05
2003-01-02
Heart Res Inst Ltd

CHEMOTACTIC FACTORS

CH685959A5
(en)

*

1992-08-24
1995-11-15
Biomedicals Ag
Diagnostic test kit for the determination of proteins.

US6030615A
(en)

*

1993-05-17
2000-02-29
The Picower Institute For Medical Research
Combination method for treating diseases caused by cytokine-mediated toxicity

US5776348A
(en)

*

1995-02-07
1998-07-07
Massachusetts Institute Of Technology
Mineral precipitation system and method for inhibiting mineral precipitate formation

CA2278248A1
(en)

1997-01-21
1998-07-23
Human Genome Sciences, Inc.
Human proteins

EP1118681A1
(en)

1998-09-29
2001-07-25
Asahi Kasei Kabushiki Kaisha
Method for controlling the release of granules

AU773265B2
(en)

*

1998-11-05
2004-05-20
Regents Of The University Of Michigan, The
S100 proteins and autoantibodies as serum markers for cancer

MY140679A
(en)

2001-05-24
2010-01-15
Avanir Pharmaceuticals
Inhibitors of macrohage migration inhibitory factor and methods for identifying the same

AU2003212246A1
(en)

*

2002-02-15
2003-09-04
Johannes Roth
Method for diagnosis of inflammatory diseases using mrp8/mrp14

EP1519749B1
(en)

2002-07-05
2009-04-08
Universite Laval
Chemotactic factor inhibitor for inhibiting inflammatory reactions

TW200418829A
(en)

2003-02-14
2004-10-01
Avanir Pharmaceutics
Inhibitors of macrophage migration inhibitory factor and methods for identifying the same

US7361474B2
(en)

*

2003-02-24
2008-04-22
United States Of America As Represented By The Department Of Veterans Affairs
Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer

EP1608397B1
(en)

2003-03-28
2008-10-15
Universite Laval
S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment

EP1656376A1
(en)

*

2003-08-22
2006-05-17
Avanir Pharmaceuticals
Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases

US20050196795A1
(en)

*

2004-02-25
2005-09-08
Siegler Katherine M.
Methods for diagnosing and treating bladder cancer

SE0400886D0
(en)

*

2004-04-02
2004-04-02
Amersham Biosciences Ab

Process of purification

WO2006005186A1
(en)

*

2004-07-13
2006-01-19
UNIVERSITé LAVAL
S100 protein inhibitors for treating leukemia

US7659087B2
(en)

2004-07-23
2010-02-09
Aspenbio Pharma, Inc.
Methods and devices for diagnosis of appendicitis

NZ580805A
(en)

2004-07-23
2011-02-25
Aspenbio Pharma Inc
Methods and devices for diagnosis of appendicitis

WO2006102191A1
(en)

2005-03-24
2006-09-28
Avanir Pharmaceuticals
Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors

GB0605689D0
(en)

*

2006-03-21
2006-05-03
Novartis Ag
Organic compounds

EP3075867B1
(en)

*

2008-09-03
2019-03-13
Quantumdx Group Limited
Sensing strategies and methods for nucleic acid detection using biosensors

EP2711682B1
(en)

2011-05-20
2019-07-10
Riken
Clarifying reagent for biological materials and use thereof

EP2748613B1
(en)

2011-10-07
2021-05-05
Baxalta GmbH
Oxmif as a diagnostic marker

EP3183581A1
(en)

*

2014-08-22
2017-06-28
Baxalta GmbH
Detection of cho-mif contaminations

Family Cites Families (9)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

DE230876C
(en)

*

US4322274A
(en)

*

1980-08-28
1982-03-30
Wilson Gregory B
Method of diagnosing cystic fibrosis patients and asymptomatic carrier of the cystic fibrosis gene

GB2125047B
(en)

1982-08-09
1986-02-19
Ciba Geigy Ag
Yeast hybrid vectors and their use for the production of polypeptides

GB8318754D0
(en)

*

1983-07-11
1983-08-10
Fagerhol M K F
Human proteins anti-sera test kits

JPS6041697A
(en)

*

1983-08-15
1985-03-05
Asahi Chem Ind Co Ltd
Novel synthesis of active protein derivative

FI86746C
(en)

1983-11-21
1992-10-12
Ciba Geigy Ag

FOERFARANDE FOERFARANDE AV MAENSKLIG VAEVNADS PLASMINOGENAKTIVATOR (TPA) MED HJAELP AV SACCHAROMYCES CEREVISIAE -JEST OCH I FOERFARANDET ANVAENDA HYBRIDVEKTORER

PT79519B
(en)

1983-11-21
1986-12-11
Ciba Geigy Ag
Process for preparing protease inhibitors based on egline compounds

JPH0672158B2
(en)

*

1984-05-24
1994-09-14
チバ−ガイギ− アクチエンゲゼルシヤフト

Purified human macrophage migration inhibitory factor

GB8915414D0
(en)

*

1989-07-05
1989-08-23
Ciba Geigy
Novel cytokines

1987

1987-09-28
DE
DE3789413T
patent/DE3789413T2/en
not_active
Expired – Fee Related

1987-09-28
ES
ES87810561T
patent/ES2052602T3/en
not_active
Expired – Lifetime

1987-09-28
EP
EP87810561A
patent/EP0263072B1/en
not_active
Expired – Lifetime

1987-09-30
FI
FI874287A
patent/FI874287A/en
not_active
IP Right Cessation

1987-10-01
PT
PT85849A
patent/PT85849B/en
not_active
IP Right Cessation

1987-10-02
AU
AU79309/87A
patent/AU7930987A/en
not_active
Abandoned

1987-10-02
IE
IE264587A
patent/IE61773B1/en
not_active
IP Right Cessation

1987-10-02
NO
NO874159A
patent/NO874159L/en
unknown

1987-10-02
DK
DK517787A
patent/DK517787A/en
not_active
Application Discontinuation

1990

1990-11-21
US
US07/617,485
patent/US5350687A/en
not_active
Expired – Fee Related

1995

1995-07-27
US
US08/508,142
patent/US5702920A/en
not_active
Expired – Fee Related

1996

1996-12-18
JP
JP8338746A
patent/JPH09188698A/en
active
Pending

Cited By (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU649226B2
(en)

*

1989-07-05
1994-05-19
Novartis Ag
Novel cytokines

Also Published As

Publication number
Publication date

FI874287A0
(en)

1987-09-30

IE872645L
(en)

1988-04-03

EP0263072B1
(en)

1994-03-23

DE3789413D1
(en)

1994-04-28

US5350687A
(en)

1994-09-27

DK517787D0
(en)

1987-10-02

EP0263072A2
(en)

1988-04-06

IE61773B1
(en)

1994-11-30

US5702920A
(en)

1997-12-30

DK517787A
(en)

1988-04-04

PT85849B
(en)

1990-07-31

EP0263072A3
(en)

1990-01-10

PT85849A
(en)

1987-11-01

JPH09188698A
(en)

1997-07-22

NO874159L
(en)

1988-04-05

NO874159D0
(en)

1987-10-02

DE3789413T2
(en)

1994-07-28

FI874287A
(en)

1988-04-04

ES2052602T3
(en)

1994-07-16

Similar Documents

Publication
Publication Date
Title

AU7930987A
(en)

1988-05-19

Human macrophage migration inhibition factor related peptide

GB2199831B
(en)

1991-04-17

Peptide derivatives

AU581367B2
(en)

1989-02-16

Chair

AU584297B2
(en)

1989-05-18

Chair

PT81887A
(en)

1986-02-01

Peptide derivatives

AU7336587A
(en)

1987-12-03

Coated dosage forms

AU579089B2
(en)

1988-11-17

Human interleukin-2-like polypeptides

AU574316B2
(en)

1988-06-30

Chair

IL81175A0
(en)

1987-08-31

Human preproinsulin-like factor i

AU590016B2
(en)

1989-10-26

Peptides

AU580748B2
(en)

1989-02-02

Novel human interferon-“ polypeptide derivative

AU578005B2
(en)

1988-10-06

Easy chair

AU5831286A
(en)

1986-12-11

Human laminin

AU7831487A
(en)

1988-03-17

Human prorelaxin

AU3446589A
(en)

1989-11-03

Tomography

AU6182886A
(en)

1987-03-05

Furniture covering

AU583668B2
(en)

1989-05-04

Chair

GB9011637D0
(en)

1990-07-11

Peptide derivatives

GB8826452D0
(en)

1988-12-14

Peptide derivatives

ZA877688B
(en)

1989-06-28

Peptide derivatives

IE860363L
(en)

1986-08-12

Peptide derivatives

AU95467S
(en)

1987-03-12

Lounging chair

MW486A1
(en)

1987-09-09

Peptide derivatives

AU5891286A
(en)

1987-02-12

Covering

GB8803479D0
(en)

1988-03-16

Polypeptide derivatives

Download PDF in English

None